Related Experiment Videos
A double-blind multicentre study comparing remoxipride, controlled release formulation, with haloperidol in
Acta Psychiatrica Scandinavica. Supplementum
|January 1, 1990
Summary
This study found that remoxipride controlled release (CR) and haloperidol showed similar efficacy in treating schizophrenia. However, remoxipride CR resulted in fewer and less severe extrapyramidal symptoms compared to haloperidol.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Trials
Background:
- Schizophrenia is a chronic mental disorder requiring effective treatment.
- Antipsychotic medications are the cornerstone of schizophrenia management.
- Extrapyramidal symptoms (EPS) are common side effects of antipsychotics, impacting patient adherence and quality of life.
Purpose of the Study:
- To compare the efficacy and safety of remoxipride in a controlled release (CR) formulation administered once daily versus haloperidol administered twice daily in patients with schizophrenia.
- To evaluate treatment-emergent extrapyramidal symptoms (EPS) and the need for anticholinergic co-administration.
Main Methods:
- A double-blind, multicentre study involving 114 patients diagnosed with schizophrenia or schizophreniform disorder (DSM-III criteria).
- Patients received either remoxipride CR (mean daily dose 385 mg) or haloperidol (mean daily dose 17 mg) for 4 weeks.
- Efficacy was assessed using the Brief Psychiatric Rating Scale (BPRS), and safety, including EPS, was evaluated using the Simpson and Angus rating scale.
Main Results:
- No significant differences in efficacy were observed between remoxipride CR and haloperidol, as indicated by similar median BPRS scores at the end of treatment.
- Treatment-emergent extrapyramidal symptoms occurred significantly more frequently and were more severe in the haloperidol group compared to the remoxipride CR group.
- Despite a statistically significant higher concurrent use of anticholinergic drugs in the haloperidol group, EPS remained more prevalent and severe.
Conclusions:
- Remoxipride CR demonstrates comparable efficacy to haloperidol in treating schizophrenia.
- Remoxipride CR offers a potentially better safety profile regarding extrapyramidal symptoms compared to haloperidol.
- Once-daily dosing of remoxipride CR may improve patient convenience and adherence while managing schizophrenia symptoms effectively.